{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06736327","nct_id":"NCT06736327","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06736327. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects will receive SKB500 once every three weeks (Q3W).","label":"SKB500","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":180,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SKB500","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","official_title":"A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Evaluate the incidence of adverse events (AEs)","timeFrame":"Up to 3 years"},{"measure":"Evaluate the incidence of serious adverse events (SAEs)","timeFrame":"Up to 3 years"},{"measure":"Evaluate the incidence of treatment related adverse events (TRAEs)","timeFrame":"Up to 3 years"},{"measure":"Evaluate the incidence of dose-limiting toxicities (DLTs)","timeFrame":"Day 1 to Day 21 in Cycle 1 in the dose escalation part"}],"references":[],"start_date":{"date":"2024-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06736327"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06736327"}